We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

By LabMedica International staff writers
Posted on 30 Jul 2014
Print article
The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research.

This notable growth will be fueled by the anticipated market entry of nine novel immunotherapies--including four novel immune checkpoint inhibitors and five novel therapeutic vaccines—in new oncology indications and/or patient populations, according to Decision Resources Group (Burlington, MA, USA). Combined, Bristol-Myers Squibb’s anti-CTLA-4 agent Yervoy and innovative immune checkpoint inhibitors that target the anti-programmed cell death-1/programmed death-ligand-1 (PD-1/PD-L1) pathway—including Bristol-Myers Squibb/Ono Pharmaceutical’s nivolumab, Merck & Co.'s pembrolizumab (MK-3475), Roche/Genentech/Chugai’s MPDL-3280A and AstraZeneca/MedImmune’s MEDI4736—should dominate the immunotherapy market and capture a remarkable 85% market share in 2022.

Other key findings from the Pharmacor Immunotherapies advisory service include: potential of anti-PD-1/PD-L1 agents: Interviewed experts are considerably excited about the potential of anti-PD-1/PD-L1 agents based on encouraging data released to date in multiple oncology indications. The added prospect of using PD-L1 expression as a potential predictive biomarker for customizing treatment fascinated interviewed experts; however, they remain watchful on this point, noting that considerable heterogeneity exists in PD-L1 expression and that good objective responses have also been reported in patients considered to have no or low levels of PD-L1 expression.

Because of the impressive early-phase data presented at the 2014 annual meeting of the American Society for Clinical Oncology (ASCO), held May 30-June 3, 2014, in Chicago (IL, USA), interviewed experts expressed enthusiasm for combination approaches involving immunotherapies—including dual blockade of the immune checkpoint pathway, combinations of immune checkpoint inhibitors with therapeutic cancer vaccines and combinations of immune checkpoint inhibitors with chemotherapy.

The therapeutic vaccines segment will see, according to Decision Resources Group, 13.6% annual sales growth over the 2012 to 2022 forecast period, although, with combined major-market sales reaching USD 1.2 billion in 2022, these agents will not reach the commercial success of immune checkpoint inhibitors.

Decision Resources Group senior business insights analyst Khurram Nawaz, MSc, commented, “A plethora of immunotherapies are in development across a wide range of oncology indications, making this drug class one of the most exciting to watch. We anticipate that nivolumab will be the sales-leading agent among immunotherapies. However, it will face direct and intense competition from other anti-PD-1/PD-L1 agents—notably from pembrolizumab in malignant melanoma and non-small-cell lung cancer—and to a lesser degree, from MPDL-3280A in non-small-cell lung cancer. Interviewed experts express mixed reactions to therapeutic vaccines and note the challenges in monitoring the efficacy of these agents. Nevertheless, they are hopeful that some vaccines will provide new therapeutic options and hold greatest promise as part of combination strategies.”

Decision Resources Group offers information and insights on critical issues within the healthcare industry.

Related Links:

Decision Resources Group


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Unit-Dose Packaging solution
HLX
New
Hepato Fibrosis Assays
Hepato Fibrosis Assays
New
Urine Drug Test
Instant-view Methadone Urine Drug Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: Schematic overview of maternal biomarker discovery using cell-free RNA during pregnancy (Photo courtesy of Circulation Research (2024). DOI: 10.1161/CIRCRESAHA.124.325024)

Maternal Blood Test Identifies Congenital Heart Diseases in Fetus

Each year, around 1,000 children are born with a single ventricle heart defect (SVHD), a condition where one of the heart's lower chambers is underdeveloped, too small, or missing a valve.... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.